Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. Abstract Text:

Julie R Gralow,Harold J Burstein,William Wood,Gabriel N Hortobagyi,Luca Gianni,Gunter von Minckwitz,Aman U Buzdar,Ian E Smith,William F Symmans,Baljit Singh,Eric P Winer,Julie R Gralow,Harold J Burstein,William Wood,Gabriel N Hortobagyi,Luca Gianni,Gunter von Minckwitz,Aman U Buzdar,Ian E Smith,William F Symmans,Baljit Singh,Eric P Winer,

PURPOSE: To review the state of the science with respect to preoperative systemic therapy and pathologic assessment in operable breast cancer. METHODS: This article reviews data presented at the National Cancer Institute State of the Science Conference on Preoperative Therapy in Invasive Breast Cancer as well as supporting published data. RESULTS: Preoperative chemotherapy in operable breast cancer has been shown to improve breast conservation rates as a result of tumor response to therapy. When patients are given preoperative systemic therapy, regimens should be the same as those established as safe and active in the adjuvant setting. At present, there are no data to suggest that systemic treatment should be tailored based on initial tumor response, or based on the extent of residual disease. In operable breast cancer, there seems to be no survival advantage from initiation of systemic therapy before surgery. A variety of clinical, imaging, and pathologic measurements are available to gauge tumor response to treatment. There is a clear correlation between tumor response in the breast and lymph nodes and both disease-free and overall survival. Pathologic complete response and other pathologic measures may be useful as surrogate end points in evaluating and understanding new therapies. CONCLUSION: In operable breast cancer, preoperative systemic therapy is effective and can improve breast conservation rates. Unless the tumor is large or the patient is in a clinical trial, postoperative adjuvant systemic therapy is the standard of care. To achieve optimal outcomes, preoperative systemic therapy must be administered as part of a coordinated, multimodality treatment program. The preoperative setting provides a unique opportunity to study the impact of systemic therapies on breast cancer biology.

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. Publishing Authors By Initials

JR Gralow,HJ Burstein,W Wood,GN Hortobagyi,L Gianni,G von Minckwitz,AU Buzdar,IE Smith,WF Symmans,B Singh,EP Winer,JR Gralow,HJ Burstein,W Wood,GN Hortobagyi,L Gianni,G von Minckwitz,AU Buzdar,IE Smith,WF Symmans,B Singh,EP Winer,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of clinical oncology : official journal of

VOLUME: 26

Page Numbers: 814-9

Journal Abbreviation: J. Clin. Oncol.

ISSN: 1527-7755

DAY: 10

MONTH: Feb

YEAR: 2008

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309333

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.

AFFILIATION: Seattle Cancer Care Alliance, Department of Medicine, 825 Eastlake Ave, EMS G3-200, Seattle, WA 98109-1023, USA. pink@u.washington.edu

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Clin Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease Related Publications

• A framework for interactive examination of automatic segmented tumors in a virtual environment.
• A simple approach to quality assurance in a complex ambulatory care setting.
• Advances in adjuvant endocrine therapy for postmenopausal women.
• Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.
• Auditory cortex mapmaking: principles, projections, and plasticity.
• Branched projections in the auditory thalamocortical and corticocortical systems.
• Commoner skin diseases of the external genitalia.
• Concurrent tonotopic processing streams in auditory cortex.
• Connections of cat auditory cortex: I. Thalamocortical system.
• Connections of cat auditory cortex: II. Commissural system.
• Connections of cat auditory cortex: III. Corticocortical system.
• Cutaneous leishmaniasis; report of a case and summary of the newer concepts.
• Drospirenone/ethinyl estradiol.
• Elastic fibers in unusual dermatoses.
• Follow-up care of patients with breast cancer.
• Herpes zoster and malignancy.
• Heterogeneity of breast cancer and implications of adjuvant chemotherapy.
• How does infiltration behavior modify the composition of ambient PM2.5 in indoor spaces? An analysis of RIOPA data.
• Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors.
• Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer.
• Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time.
• Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
• Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
• Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions.
• Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
• Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study.
• Sarcoidosis mimicking metastatic breast cancer.
• The pharmacologic management of premenstrual dysphoric disorder.
• Uterine inversion associated with bicornuate uterus.
• Vascular compliance in the cardiometabolic syndrome.